Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer

Studies have demonstrated that men with Prostate Cancer (PCa) harboring BRCA2/BRCA1 genetic aberrations, are more likely to have worse disease and a poorer prognosis. A mutation in BRCA2 is known to confer the highest risk of PCa for men (8.6 fold in men ≤65 yea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ciara S. McNevin, Karen Cadoo, Anne-Marie Baird, Pierre Murchan, Orla Sheils, Ray McDermott, Stephen Finn
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	<i>BRCA2</i> <i>BRCA1</i> biomarker prostate cancer gene mutation screening Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ca595d192acd4bb1bc768ae9dca5dfe3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca595d192acd4bb1bc768ae9dca5dfe3
record_format	dspace
spelling	oai:doaj.org-article:ca595d192acd4bb1bc768ae9dca5dfe32021-11-25T17:02:46ZPathogenic <i>BRCA</i> Variants as Biomarkers for Risk in Prostate Cancer10.3390/cancers132256972072-6694https://doaj.org/article/ca595d192acd4bb1bc768ae9dca5dfe32021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5697https://doaj.org/toc/2072-6694Studies have demonstrated that men with Prostate Cancer (PCa) harboring <i>BRCA2/BRCA1</i> genetic aberrations, are more likely to have worse disease and a poorer prognosis. A mutation in <i>BRCA2</i> is known to confer the highest risk of PCa for men (8.6 fold in men ≤65 years) making <i>BRCA</i> genes a conceivable genomic biomarker for risk in PCa. These genes have attracted a lot of research attention however their role in the clinical assessment and treatment of PCa remains complex. Multiple studies have been published examining the relationship between prostate cancer and <i>BRCA</i> mutations. Here <i>BRCA</i> mutations are explored specifically as a biomarker for risk in PCa. It is in this context, we examined the prognostic, clinical and therapeutic role of <i>BRCA2/BRCA1</i> mutations across the evolution of PCa. The impact of the inclusion of <i>BRCA</i> genes on genetic screening will also be outlined.Ciara S. McNevinKaren CadooAnne-Marie BairdPierre MurchanOrla SheilsRay McDermottStephen FinnMDPI AGarticle<i>BRCA2</i><i>BRCA1</i>biomarkerprostate cancergene mutationscreeningNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5697, p 5697 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	<i>BRCA2</i> <i>BRCA1</i> biomarker prostate cancer gene mutation screening Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	<i>BRCA2</i> <i>BRCA1</i> biomarker prostate cancer gene mutation screening Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ciara S. McNevin Karen Cadoo Anne-Marie Baird Pierre Murchan Orla Sheils Ray McDermott Stephen Finn Pathogenic <i>BRCA</i> Variants as Biomarkers for Risk in Prostate Cancer
description	Studies have demonstrated that men with Prostate Cancer (PCa) harboring <i>BRCA2/BRCA1</i> genetic aberrations, are more likely to have worse disease and a poorer prognosis. A mutation in <i>BRCA2</i> is known to confer the highest risk of PCa for men (8.6 fold in men ≤65 years) making <i>BRCA</i> genes a conceivable genomic biomarker for risk in PCa. These genes have attracted a lot of research attention however their role in the clinical assessment and treatment of PCa remains complex. Multiple studies have been published examining the relationship between prostate cancer and <i>BRCA</i> mutations. Here <i>BRCA</i> mutations are explored specifically as a biomarker for risk in PCa. It is in this context, we examined the prognostic, clinical and therapeutic role of <i>BRCA2/BRCA1</i> mutations across the evolution of PCa. The impact of the inclusion of <i>BRCA</i> genes on genetic screening will also be outlined.
format	article
author	Ciara S. McNevin Karen Cadoo Anne-Marie Baird Pierre Murchan Orla Sheils Ray McDermott Stephen Finn
author_facet	Ciara S. McNevin Karen Cadoo Anne-Marie Baird Pierre Murchan Orla Sheils Ray McDermott Stephen Finn
author_sort	Ciara S. McNevin
title	Pathogenic <i>BRCA</i> Variants as Biomarkers for Risk in Prostate Cancer
title_short	Pathogenic <i>BRCA</i> Variants as Biomarkers for Risk in Prostate Cancer
title_full	Pathogenic <i>BRCA</i> Variants as Biomarkers for Risk in Prostate Cancer
title_fullStr	Pathogenic <i>BRCA</i> Variants as Biomarkers for Risk in Prostate Cancer
title_full_unstemmed	Pathogenic <i>BRCA</i> Variants as Biomarkers for Risk in Prostate Cancer
title_sort	pathogenic <i>brca</i> variants as biomarkers for risk in prostate cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/ca595d192acd4bb1bc768ae9dca5dfe3
work_keys_str_mv	AT ciarasmcnevin pathogenicibrcaivariantsasbiomarkersforriskinprostatecancer AT karencadoo pathogenicibrcaivariantsasbiomarkersforriskinprostatecancer AT annemariebaird pathogenicibrcaivariantsasbiomarkersforriskinprostatecancer AT pierremurchan pathogenicibrcaivariantsasbiomarkersforriskinprostatecancer AT orlasheils pathogenicibrcaivariantsasbiomarkersforriskinprostatecancer AT raymcdermott pathogenicibrcaivariantsasbiomarkersforriskinprostatecancer AT stephenfinn pathogenicibrcaivariantsasbiomarkersforriskinprostatecancer
_version_	1718412803432251392

Pathogenic <i>BRCA</i> Variants as Biomarkers for Risk in Prostate Cancer

Ejemplares similares